Verve Therapeutics
Victoria Bartlett is Vice President, Alliance and Program Management at Verve Therapeutics. She has over 20 years of industry experience, predominantly in program, alliance, and portfolio management. Dr. Bartlett joins us from Ionis Pharmaceuticals, where she worked as senior director of alliance management and was responsible for the Ionis partnerships within the cardio-renal franchise. Prior to that, Dr. Bartlett was with Akcea Therapeutics, as senior director of program and alliance management, where she led the phase 2 clinical programs for three antisense oligonucleotide programs targeting Apo(a) (pelacarsen), ANGPTL3 (vupanorsen), and APOCIII. In addition, she held program, alliance, and portfolio positions at CRISPR Therapeutics, Moderna, Pfizer and Wyeth Research. Dr. Bartlett has both a Ph.D. and B.Sc. in Pharmacology from the University of Liverpool and she spent 4 years as a postdoctoral fellow at Harvard Medical School.
Verve Therapeutics
59 followers
Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.